Over the past year, headlines across industry and consumer media have highlighted FDA warnings on the dangers of gadolinium-based contrast agents. To date, it has become common knowledge and a FDA black box warning that gadolinium-based agents run the risk of causing Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy (NSF/NFD).

Since its clinical adoption in the early 1990s, anesthesia agent monitoring has evolved significantly from standalone units to modules that are used in multiparameter monitoring systems. According to the American Society of Anesthesiologists (ASA), over 40 million anesthetics are delivered each year in the United States, irrespective of the care setting.